A Small Pharma Company Goes Public on BSE SME

Everything a Beginner Needs to Know

From 'What is an SME IPO?' to Financials, Promoters & Risks — Explained Simply

By Kanishk Dev Bangia | NISM Series XV Certified Research Analyst

Last Updated: May 2026 | NISM Reg. No: NISM-202300182946

1. What Is This Story About?

The IPO of a pharma marketing firm that has been running for 20 years and is located in Nagpur, Maharashtra, will be listed on BSE SME from May 2026 onwards. The total capital amount that the company wants to raise is ₹11.61 crore. This is the first time the company has decided to go public through the IPO route.

This blog is an easy-to-follow guide for you to understand everything about the company, the promoters, the financials, and the risks involved.

2. Jargon Buster — Key Terms Explained Simply

What is an IPO?

Initial Public Offerings (IPOs) are made by private firms where they sell their stocks to the general public for the first time. Once listed, any individual who holds a demat account can trade those shares.

What is an SME IPO?

An IPO for a Small and Medium Enterprise (SME) is a type of IPO that is specific to small enterprises that have a relatively lower income and capitalization. Such shares are floated on a particular platform like BSE SME or NSE Emerge, which entails lesser requirements for listing compared to the main stock exchange.

What is a Book Build Issue?

In the book-build method of an IPO, the company fixes the price band (for instance, ₹41 to ₹43), and then investors place their bids within that price band. The final determination of the price depends upon the demand for the issue, which is a market-driven approach, not like the fixed price approach.

What is a Fresh Issue vs OFS?

A Fresh Issue implies that the firm makes a fresh issue of shares and retains the capital generated from it for purposes such as paying off debts, expansion, and financing operations. An Offer for Sale refers to existing shareholders selling their shares and retaining the proceeds while the firm receives nothing. This particular IPO consists entirely of a Fresh Issue.

What is an Asset-Light Business Model?

Rather than investing in factories or large machinery, the business chooses to outsource its production processes to third parties while concentrating solely on brand building, marketing, and logistics operations. This approach demands relatively lower initial investment yet potentially offers greater ROE; however, it increases reliance on outside sources.

3. About the Company

The marketing pharmaceutical company was founded in the year 2005 in Nagpur, Maharashtra. The company is entirely asset light since it does not have any manufacturing facility. The company partners with 15 different third party contract manufacturers for manufacturing of its products according to World Health Organization Good Manufacturing Practices (GMP) and ISO standards.

The company markets products under five different sub-brands, which cater to different medical segments.

The Five Sub-Brands

• Multi-speciality portfolio - 42 products across general medicines comprising proteolytic enzymes.
• Cardio-diabetic medications - 54 products targeting chronic diseases such as high blood pressure and diabetes.
• Pediatrics and gynecological medicines - 18 products for children and gynecology applications.
• Critical care and injectables – 22 products for hospital use .
• Oncology wellness - 10 niche products for patients undergoing cancer treatment.

Total no. of products: approx. 146 formulations. Medical specializations include cardiology, neurology, gastroenterology, pediatrics, and oncology wellness.

Distribution Network

• Products sold via 7–8 main distributors (mostly wholesalers)
• Geography: Maharashtra and Madhya Pradesh, which contribute around 70–76% of total income
• Company operations extended to more than one state in India
• More than 99% of total sales are made via wholesalers
• Employees: 99 as of August 2025; sales staff make up about 75% of all employees

4. The Financials — What the Numbers Show

Here is a snapshot of the company's financial performance over three years, based on publicly available data:

Important Financial Analysis:

• Increase in sales from ₹19.85 crore in FY23 to ₹28.06 crore in FY25, i.e., an increase of 41%
• Increase in net income from ₹26 lakh in FY23 to ₹2.83 crore in FY25, i.e., an increase of nearly 10x
• The EBITDA margin increased from 11% to nearly 21%, suggesting good operating leverage
• Decrease in debt/equity ratio from 3.09x to 1.07x, implying that the company is working on reducing its debt levels
• Improvement in interest coverage from 1.25x to 4.11x

5. The IPO — All Key Details at a Glance

What is QIB, HNI, and Retail? (Quick Explanation)

• Qualified Institutional Buyers (QIBs): Large institutional buyers, such as mutual funds, insurance companies, and foreign institutional investors. Reservation percentage is 50%.
• High Net-worth Individuals/Non-institutional Investors (HNI/NII): High net-worth individual applicants, who apply to buy more than Rs. 2 lakh. Reservation percentage is 15%.
• Retail Investors: Individual applicants who apply to buy less than Rs. 2 lakh.

6. Who Are the Promoters & Key Management?

The company was founded by a pharmacy graduate who started the firm in 2005 based on the vision of creating a pharmaceutical marketing brand that emphasizes quality. The promoters and management team have a total of over 50 years of collective experience in the areas of pharmaceutical marketing and distribution.

The Two Promoters

Amol Laxmikant Mujumdar (Age 54): Promoter, Chairman & Managing Director (MD). Holds 27,49,988 shares — 39.85% of pre-IPO equity capital. A pharmacy graduate who founded the company.

Swapan Premprakash Khandelwal (Age 57): Promoter & Whole-Time Director. Also holds 27,49,988 shares — 39.85% of pre-IPO equity capital. Together, both promoters hold approximately 79.7% of the company before the IPO.

Senior Management Team

• Prashant Shrikrishna Karkare — Chief Operating Officer (COO)

• Avinash Pandurang Ambulkar — Chief Technology Officer (CTO)

• Mehul Hari Ranade — Chief Financial Officer (CFO)

• Prashant Vithalrao Rahate — Director

• Renuka Saurabh Borole — Vice President, Marketing

• Shraddha Kiran Kulkarni — Vice President, Sales

7. Key Risks — What Beginners Must Understand

Every IPO comes with risks. The following are factual challenges that analysts and documents have highlighted for this company. Understanding these is important for anyone forming a view about a business.

Business & Operational Risks

• No manufacturing: 100% dependence on 15 third party contract manufacturers with lead times between 15 days and 60 days. Any failure on the part of these companies regarding quality, delivery, or compliance directly affects the company.
• Distribution: There are only 7-8 distributors who generate almost all income. The loss of just one of these major distributors can have an adverse impact on the company’s sales figures.
• Geographical concentration: 70-76% of the company’s income comes from Maharashtra and Madhya Pradesh, making geographical dependence very important.
• Promoters’ group revenue dependence: Three promoters' group companies acting as distributors generated 22.04% of the company’s total income.

Financial Risks

• Capital obtained via IPO will be used for repaying debt; it will not support any growth and development of the firm.
• Trade receivables are increasing from ₹862 lakh in FY23 to ₹1,290 lakh in Q3 FY26 because of the 60 days of credit period offered to distributors, which impacts working capital.
• Ongoing cases in litigation for tax related matters – ₹271.23 lakhs in Direct Tax and ₹63.70 lakhs in Indirect Tax issues.
• Non-compliance regarding regulatory requirements – Late ROC and GST payment penalty charges reported.

Market & Sector Risks

• The pharmaceutical marketing segment is intensely competitive, with several existing firms boasting greater distribution networks and brand name value.
• There is pressure on pricing within the pharmaceutical industry, particularly for drugs that are off patent.
• Any regulatory changes in drug pricing or health care policies (like NPPA pricing) may impact the company’s product range and earnings.
• The SME IPO market lacks liquidity, as stocks listed on the BSE SME platform trade less frequently compared to regular stock market shares.

8. India's Pharmaceutical Marketing Sector — The Bigger Picture

India ranks third globally in terms of volume in the pharmaceuticals market and is a key producer of generics. A new batch of firms is preferring the role of 'market' over that of 'manufacturer,' producing through contract manufacturing and focusing on marketing and distribution.

• The Indian domestic pharma market will reach $65 billion in 2030 (vs $50 billion in 2024)
• The prevalence of chronic lifestyle diseases such as diabetes, hypertension, and cardiovascular disorders ensures continued demand for formulations that are exactly what this company offers
• Government programs and increased awareness have increased the availability of prescription drugs in tier-2 and tier-3 cities, which is precisely where this company operates
• P/E ratio in the industry for comparable pharmaceutical companies varies between 7.57× and 28.94×, averaging 18.26×

The asset-light pharma marketing model is increasingly popular among smaller Indian companies, as it allows rapid scaling without the capital expenditure burden of building GMP-certified manufacturing plants.

Disclaimer:

This is written for educational and informational purposes only. Nothing here constitutes investment advice or a recommendation to buy or sell securities. All data is sourced from publicly available information. Investments in securities markets are subject to market risks — please read all offer documents carefully before investing.